The circulating cell-free microrna profile in systemic sclerosis is distinct from both healthy controls and

Journal of Rheumatology

Volumn 42, Issue 2, 2015, Pages 214-220

  Steen, Samantha O ^a   Iversen, Line V ^b   Carlsen, Anting Liu ^a   Burton, Mark ^c   Nielsen, Christoffer T ^b   Jacobsen, Søren ^b   Heegaard, Niels H H ^a,c  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Classification; Diagnosis; MicroRNA; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

MICRORNA; MICRORNA 125B; MICRORNA 14; MICRORNA 142 3P; MICRORNA 145 5P; MICRORNA 146A; MICRORNA 150; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 181B; MICRORNA 203; MICRORNA 208; MICRORNA 20A; MICRORNA 21; MICRORNA 223; MICRORNA 26; MICRORNA 27A 3P; MICRORNA 29A; MICRORNA 29B 3P; MICRORNA 29C 3P; MICRORNA 34A; MICRORNA 375; MICRORNA 383; MICRORNA 409 3P; MICRORNA 423 5P; MICRORNA 590 5P; MICRORNA 638; MICRORNA 92A; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; BLOOD; CROSS-SECTIONAL STUDY; DIFFERENTIAL DIAGNOSIS; GENETICS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICRORNAS; MIDDLE AGED; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

EID: 84923210494     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140502     Document Type: Article

References (38)

1. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011;40:78-83.
2. van der Slot AJ, Zuurmond AM, Bardoel AF, Wijmenga C, Pruijs HE, Sillence DO, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 2003;278:40967-72.
3. van der Slot AJ, Zuurmond AM, van den Bogaerdt AJ, Ulrich MM, Middelkoop E, Boers W, et al. Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. Matrix Biol 2004;23:251-7.
4. van der Slot AJ, van Dura EA, de Wit EC, De Groot J, Huizinga TW, Bank RA, et al. Elevated formation of pyridinoline cross-links by profibrotic cytokines is associated with enhanced lysyl hydroxylase 2b levels. Biochim Biophys Acta 2005;1741:95-102.
5. Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, Makino T, et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012;188:3573-83.
6. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111-22.
7. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009;136:26-36.
8. Sonkoly E, Pivarcsi A. Advances in microRNAs: implications for immunity and inflammatory diseases. J Cell Mol Med 2009; 13:24-38.
9. Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010;62:1733-43.
10. Dakhlallah D, Batte K, Wang Y, Cantemir-Stone CZ, Yan P, Nuovo G, et al. Epigenetic regulation of miR-17-92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013;187:397-405.
11. Li H, Yang R, Fan X, Gu T, Zhao Z, Chang D, et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int 2012;32:307-13.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
13. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50:298-301.
14. Carlsen AL, Schetter AJ, Nielsen CT, Lood C, Knudsen S, Voss A, et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum 2013;65:1324-34.
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
16. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
17. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
18. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012;130:1378-86.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, Ser B 1995;57:289-300.
20. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011;6:e20769.
21. Makino K, Jinnin M, Kajihara I, Honda N, Sakai K, Masuguchi S, et al. Circulating miR-142-3p levels in patients with systemic sclerosis. Clin Exp Dermatol 2012;37:34-9.
22. Sonkoly E, Pivarcsi A. microRNAs in inflammation. Int Rev Immunol 2009;28:535-61.
23. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011;57:833-40.
24. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res 2012;5:492-7.
25. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009;16:961-6.
26. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010;42:1348-54.
27. Shan SW, Fang L, Shatseva T, Rutnam ZJ, Yang X, Du W, et al. Mature miR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways. J Cell Sci 2013;126:1517-30.
28. Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, Du WW, et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 2009;11:1031-8.
29. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008;133:217-22.
30. Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H, et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res 2008;68:5540-5.
31. Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem 2013;288:10819-29.
32. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805-10.
33. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001;44:474-80.
34. Danger R, Pallier A, Giral M, Martinez-Llordella M, Lozano JJ, Degauque N, et al. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. J Am Soc Nephrol 2012;23:597-606.
35. Wang Y, Gu J, Roth JA, Hildebrandt MA, Lippman SM, Ye Y, et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res 2013;73:4801-9.
36. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-wen X, et al. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002;46:1857-65.
37. Kawakami T, Ihn H, Xu W, Smith E, Leroy C, Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
38. Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998;160:2539-45.